Related Experiment Video
Updated: Aug 10, 2026
09:03
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
Autoantibodies in experimental autoimmune hepatitis
A W Lohse1, S Brunner, A Kyriatsoulis
1I. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität, Mainz, Federal Republic of Germany.
Journal of Hepatology
|January 1, 1992
Summary
In experimental autoimmune hepatitis (EAH) models, autoantibodies develop but do not drive disease progression. These findings suggest T cells are key drivers, not autoantibodies, in this liver inflammation model.
Area of Science:
- Immunology
- Hepatology
- Autoimmunity
Background:
- Experimental autoimmune hepatitis (EAH) is a mouse model for autoimmune liver disease.
- Autoreactive T cells are implicated in EAH pathogenesis.
- The role of autoantibodies in EAH requires further investigation.
Purpose of the Study:
- To investigate the occurrence and role of liver autoantibodies in a mouse model of experimental autoimmune hepatitis.
- To compare EAH autoantibodies with those found in human autoimmune chronic active hepatitis.
Main Methods:
- Induction of EAH in mice using syngeneic soluble liver antigens and complete Freund's adjuvant.
- Monitoring of autoantibody titers, liver histology, and biochemical markers of disease activity.
- Characterization of autoantibody targets.
Main Results:
- Characteristic liver autoantibodies emerged several weeks post-induction in EAH mice.
- Autoantibody titers increased even after histological and biochemical signs of disease regressed.
- Identified autoantibodies in EAH recognized different autoantigens compared to human autoimmune chronic active hepatitis.
Conclusions:
- Autoantibodies are produced during experimental autoimmune hepatitis in mice.
- These autoantibodies do not appear to play a critical role in the pathogenesis of EAH.
- The findings highlight the importance of T cell-mediated immunity in EAH pathogenesis.
